Indeed, recent studies demonstrated that due to the intrinsic heterogeneity of intratumor, EGFR‐mutated NSCLC could seldom carry additional BRAF mutations, which is considered a predictor of resistance to EGFR inhibitors and tumor rapid progress.25, 26. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.